Open Access

Choice of antithrombotic agent in ACS: REACT-ing to recent trials.

Topic: Pharmacotherapy
Organised by Radcliffe Cardiology, supported by AstraZeneca in the form of an educational grant

Presentation

About the speaker

Professor Stefan James

Uppsala University, UCR-Uppsala Clinical Research Center, Uppsala (Sweden)
32 presentations
0 follower

5 more presentations in this session

Welcome.

Speaker: Professor K. Huber (Vienna, AT)

Thumbnail

Pre-treatment in NSTE-ACS – dead or alive?

Speaker: Professor D. Capodanno (Catania, IT)

Thumbnail

When to leave aspirin behind?

Speaker: Professor R. Mehran (New York, US)

Thumbnail

Q&A.

Speaker: Professor K. Huber (Vienna, AT) Professor D. Capodanno (Catania, IT) Professor S. James (Uppsala, SE) Professor R. Mehran (New York, US)

Thumbnail

Summary and close.

Speaker: Professor K. Huber (Vienna, AT)

Thumbnail

Access the full session

Navigating the Antithrombotic Maze: What to do for Your ACS Patients in the Era of Contemporary PCI

Speakers: Professor S. James, Professor K. Huber, Professor D. Capodanno, Professor R. Mehran, Professor K. Huber...
Thumbnail

About the event

Image

ESC CONGRESS 2020 - The Digital Experience

28 August - 1 September 2020

Sessions Presentations

Related content

ESC Premium Access

MASTER DAPT: dual antiplatelet therapy after coronary stenting in high bleeding risk patients

28 August 2021

ESC Premium Access

TAVI challenges: antithrombotic management after TAVI and prevention of valve thrombosis and HALT.

28 August 2021

Open Access

Panel Discussion: The case for combination therapy: The way forward in intensive LDL-c management?

27 August 2021

This platform is supported by

logo Novo Nordisk